Evidence map›Paper›PMID 39110308›Full record

ReviewCardiovascular drugs and therapy2025

Levosimendan: A New Therapeutical Strategy in Patients with Renal Insufficiency.

Xinwen Liu, Mengkai Lu, Yanna Yu, Nannan Shen, Haijiang Xia, Jiana Shi, Yongping Fu, Ying Hu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinwen LiuDepartment of Pharmacy, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
Mengkai LuDepartment of Pharmacy, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
Yanna YuDepartment of Pharmacy, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
Nannan ShenDepartment of Pharmacy, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
Haijiang XiaDepartment of Cardiovascular Medicine, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
Jiana ShiClinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Yongping FuDepartment of Cardiovascular Medicine, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China. fuyongping@usx.edu.cn.ORCID 0000-0001-8834-0787
Ying HuClinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. huying@hmc.edu.cn.ORCID 0009-0002-6067-5029

Funding

National Natural Science Foundation of China 72204073Science and Technology Projects in the Zhejiang Province Department of Education Y202146979Science and Technology Projects in the Zhejiang Province Department of Education Y202249053Shaoxing Health Science and Technology Plan Project KY2022066the Ministry of Education Industry-University Cooperative Education Project 22087043124451Zhejiang Medical and Health Science and Technology 2023KY491Zhejiang Medical Association Clinical Medicine Project 2022ZYC-Z37Zhejiang Medical Association Clinical Medicine Project 2023ZYC-A55
6 · The paper itself

Abstract

Levosimendan, a Ca2 + sensitizer with positive inotropic effects, is primarily employed for the short-term treatment of acute decompensated heart failure (ADHF). Levosimendan exerts renal function protection through various mechanisms, including anti-apoptosis, anti-inflammatory, and antioxidant effects in vivo. Additionally, levosimendan may have a protective effect on individuals with heart failure and renal insufficiency, as well as on renal function impairment after cardiac surgery. However, the application of levosimendan in patients with severe renal dysfunction remains controversial. This article delves into the use of levosimendan in severe renal insufficiency, explores its impact on renal function, and provides a comprehensive overview of its impact on renal function after cardiac surgery.

Indexed as

Cardiotonic AgentsHeart FailureHydrazonesKidneyPyridazinesRenal InsufficiencyAnimalsCardiac Surgical ProceduresHumansSimendanCardiotonic AgentsHydrazonesPyridazinesSimendanCardiac surgeryHeart failureKidneyLevosimendan

Identifiers

PMID39110308

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.